|Time Commitment:||2 Hrs 30 min over 45 days|
|Credits Available:||3.25 AMA PRA Category 1 Credits™|
MS is the leading cause of non-traumatic disability in adults over the age of 50 and has become a focus of evolving research. In just the past two decades, a greater understanding of the pathogenesis of MS has led to a litany of new FDA approved therapies. In fact, there are now 18 DMTs representing nine therapeutic classes approved for use in the US with multiple late stage medications poised to join them. This curriculum
is designed to help participants improve their MS management skills by distilling the most relevant and valuable information for their patients.
This curriculum is designed to help participants improve their MS management skills by distilling how recent developments in MS therapeutics are relevant and applicable to clinical practice.
In Module 1, Drs Naismith and Subei will discus novel S1P receptor modulators – siponimod and ozanimod – and how they aim to improve upon traditional fingolimod.
In Module 2, Drs Naismith and Subei will dive into recently approved DMTs from other established medication pathways.
In Module 3, Drs Naismith and Subei will review new and emerging DMTs with unique mechanisms of action.
This final assessment is designed to assess knowledge gained from this activity regarding recent developments in MS therapeutics and how they are relevant and applicable to clinical practice.
This discussion will be based on the group’s collective responses to the self-assessments in the self-study modules. The focus will be topics where the most heterogeneity between group members and/or divergence from group leaders’ recommendations is seen.
This discussion will center around responses to the group tasks, emphasizing your own questions, points of uncertainty, and disagreements. It will allow for open dialogue surrounding strategic decision making in order to help guide useful ways of thinking when faced with carrying clinical scenarios.
This Group Task will involve discussion of real world experience with new agents and strategies for multiple sclerosis. You will have the opportunity to gauge your own strategies and pose questions surrounding obstacles in day-to-day practice.
Not all patients respond well to all therapies. This Group Task will allow you to present/view challenging clinical scenarios of patients who are resistant to treatment efforts or experiencing difficult side effects.